Clinical Trials | September 23, 2025
Roche's Giredestrant combination meets phase III endpoints in advanced breast cancer
Importantly, the combination of giredestrant and everolimus was well tolerated
Importantly, the combination of giredestrant and everolimus was well tolerated
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Phase 1 has a total reactor capacity of 440 kL with 63 reactors
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
Subscribe To Our Newsletter & Stay Updated
